AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25141962 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (indium gallium aluminum phosphorus (InGaAIP) laser operated at 660 nm) applied five days a week before each radiotherapy session.
Number of subjects: 52
Study 25141962 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied five days a week before each radiotherapy session.
Number of subjects: 52
Study 24251745 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise (4-min cycle ergometer exercise at 80% of ventilation threshold)
Number of subjects: 18
Study 24251745 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained females)
Number of subjects: 18
Study 24251745 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise
Number of subjects: 18
Study 20452927 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum infusion (CI) in treatment classes
Number of subjects: 343
Study 20452927 — intervention group
Group type: COMPARATOR
Intervention: Control group (no curriculum infusion)
Number of subjects: 343
Study 18370832 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (measured by waist circumference and total body fat percentage)
Number of subjects: 550
Study 18370832 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight subjects
Number of subjects: 550
Study 18370832 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 550
Study 16572301 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior observation in training intervention agents
Number of subjects: 0
Study 16572301 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior observation in delivery of key intervention conditions
Number of subjects: 0
Study 16572301 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior observation in measuring client responses
Number of subjects: 0
Study 16572301 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior observation in measuring short-term risk reduction
Number of subjects: 0
Study 16572301 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior observation in measuring long-term change
Number of subjects: 0
Study 14517785 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg intravenous cyclosporine
Number of subjects: 73
Study 14517785 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg intravenous cyclosporine
Number of subjects: 73
Study 10379634 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 0
Study 10379634 — intervention group
Group type: COMPARATOR
Intervention: Isradipine SRO (2.5 mg)
Number of subjects: 0
Study 10379634 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg)
Number of subjects: 0
Study 10379634 — intervention group
Group type: COMPARATOR
Intervention: Spirapril (6 mg)
Number of subjects: 0
Study 8884757 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg vincamine twice daily
Number of subjects: 142
Study 8884757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 1647531 — intervention group
Group type: EXPERIMENTAL
Intervention: High compliance enhancement group (wheat bran fiber supplement 18 g/day)
Number of subjects: 180
Study 1647531 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium compliance enhancement group (wheat bran fiber supplement 18 g/day)
Number of subjects: 180
Study 1647531 — intervention group
Group type: EXPERIMENTAL
Intervention: Low compliance enhancement group (wheat bran fiber supplement 18 g/day)
Number of subjects: 180
Study 1647531 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive compliance enhancement group
Number of subjects: 180
Study 1647531 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 180
Study 6195201 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% gamma benzene hexachloride (GBH) lotion applied for 6 hours
Number of subjects: 2076
Study 6195201 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% gamma benzene hexachloride (GBH) lotion applied for 12 to 24 hours
Number of subjects: 2076
Study 6195201 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% gamma benzene hexachloride (GBH) lotion applied for 2 hours
Number of subjects: 2076
Study 6195201 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated persons with scabies)
Number of subjects: 2076
Study 31100620 — intervention group
Group type: COMPARATOR
Intervention: n-3 PUFA supplementation
Number of subjects: 484
Study 31100620 — intervention group
Group type: COMPARATOR
Intervention: Diet counselling
Number of subjects: 484
Study 31100620 — intervention group
Group type: EXPERIMENTAL
Intervention: LBP levels above median
Number of subjects: 484
Study 31100620 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD14 levels above median
Number of subjects: 484
Study 28286376 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NPPT (ANPPT)
Number of subjects: 44
Study 28286376 — intervention group
Group type: COMPARATOR
Intervention: Barker's Vacuum Pack NPPT (BVP)
Number of subjects: 44
Study 25828109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare Metal Stents (BMS)
Number of subjects: 43
Study 25828109 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus Eluting Stents (BES)
Number of subjects: 43
Study 25828109 — intervention group
Group type: COMPARATOR
Intervention: Control (BMS and BES)
Number of subjects: 43
Study 23314556 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (500 µg folic acid, 500 µg vitamin B12, 50 mg vitamin B6), 1200 IU vitamin D, and 456 mg calcium
Number of subjects: 50
Study 21911018 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 0
Study 21911018 — intervention group
Group type: COMPARATOR
Intervention: No chewing (control)
Number of subjects: 0
Study 19817285 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement under arthroscopy (Group A)
Number of subjects: 90
Study 19817285 — intervention group
Group type: COMPARATOR
Intervention: Local block therapy (Group B)
Number of subjects: 90
Study 19817285 — intervention group
Group type: COMPARATOR
Intervention: Open operation (Group C)
Number of subjects: 90
Study 17100372 — intervention group
Group type: EXPERIMENTAL
Intervention: Halogen light stimulation test (LST)
Number of subjects: 176
Study 17100372 — intervention group
Group type: COMPARATOR
Intervention: Control (NST)
Number of subjects: 176
Study 15531662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol
Number of subjects: 292
Study 15531662 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17beta-estradiol
Number of subjects: 292
Study 15531662 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate
Number of subjects: 292
Study 15531662 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral testosterone
Number of subjects: 292
Study 15531662 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 292
Study 15531662 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives
Number of subjects: 292
Study 11419712 — intervention group
Group type: EXPERIMENTAL
Intervention: Grated fresh Golden Delicious apple (DBPCFC)
Number of subjects: 27
Study 11419712 — intervention group
Group type: EXPERIMENTAL
Intervention: Open food challenge with whole fresh apple
Number of subjects: 27
Study 11419712 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE against Golden Delicious apple
Number of subjects: 27
Study 11419712 — intervention group
Group type: COMPARATOR
Intervention: Placebo reaction
Number of subjects: 27
Study 11419712 — intervention group
Group type: COMPARATOR
Intervention: Skin prick test (SPT), leukocyte histamine release (HR), immunoblotting experiments
Number of subjects: 27
Study 9039199 — intervention group
Group type: EXPERIMENTAL
Intervention: Butenafine 1% cream applied once daily for 4 weeks
Number of subjects: 80
Study 9039199 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied once daily for 4 weeks
Number of subjects: 80
Study 7911176 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean alpha-linolenic acid-rich diet
Number of subjects: 605
Study 7911176 — intervention group
Group type: COMPARATOR
Intervention: Usual post-infarct prudent diet
Number of subjects: 605
Study 3594491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant oral Bestatin treatment (30 mg daily for at least 1 year)
Number of subjects: 151
Study 3594491 — intervention group
Group type: COMPARATOR
Intervention: No Bestatin (Control)
Number of subjects: 151
Study 31945065 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0
Study 31945065 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 30782906 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg adrecizumab
Number of subjects: 300
Study 30782906 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg adrecizumab
Number of subjects: 300
Study 30782906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 30782906 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrecizumab (2 and 4 mg/kg)
Number of subjects: 300
Study 28446656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3802
Study 28446656 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education control
Number of subjects: 3802
Study 25831450 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered Dietitian
Number of subjects: 87
Study 25831450 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor
Number of subjects: 87
Study 25831450 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 87
Study 23167309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispensed analgesia (group 'dispensed')
Number of subjects: 200
Study 23167309 — intervention group
Group type: COMPARATOR
Intervention: Advised without analgesia (group 'advised')
Number of subjects: 200
Study 21305612 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (ESC)
Number of subjects: 43
Study 21305612 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (DUL)
Number of subjects: 43
Study 21305612 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (ESC and DUL)
Number of subjects: 43
Study 18223503 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (100 mL supplemented yogurt per day for 15 days)
Number of subjects: 24
Study 18223503 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt (100 mL unsupplemented yogurt per day for 15 days)
Number of subjects: 24
Study 18223503 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 24
Study 18223503 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt
Number of subjects: 24
Study 16633813 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session, small-group stress management program
Number of subjects: 300
Study 16633813 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 300
Study 14562640 — intervention group
Group type: EXPERIMENTAL
Intervention: Unkei-to (7.5 g/d)
Number of subjects: 103
Study 10632423 — intervention group
Group type: EXPERIMENTAL
Intervention: follitropin-alpha (Gonal-F)
Number of subjects: 44
Study 10632423 — intervention group
Group type: COMPARATOR
Intervention: follitropin-beta (Puregon)
Number of subjects: 44
Study 9235004 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg fentanyl
Number of subjects: 10
Study 9235004 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg fentanyl plus 3 micrograms/kg clonidine
Number of subjects: 10
Study 1344707 — intervention group
Group type: EXPERIMENTAL
Intervention: Camit S1 data analysis
Number of subjects: 19
Study 1344707 — intervention group
Group type: COMPARATOR
Intervention: Conventional log-book method
Number of subjects: 19
Study 1344707 — intervention group
Group type: EXPERIMENTAL
Intervention: Camit S2
Number of subjects: 19
Study 1344707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadmo simulation programs
Number of subjects: 19
Study 3898291 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg, administered 3 times a week, subcutaneously for 6 weeks)
Number of subjects: 36
Study 3898291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered 3 times a week, subcutaneously for 6 weeks)
Number of subjects: 36
Study 31058892 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer heading (n = 18) - executed 10 headers with soccer balls projected at a velocity of 25 mph over 10 min.
Number of subjects: 34
Study 31058892 — intervention group
Group type: COMPARATOR
Intervention: Kicking (n = 16) - followed the same protocol with 10 kicks.
Number of subjects: 34
Study 30172453 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy (45 Gy/25 fractions plus a boost) and concomitant fluorouracil and cisplatin at weeks 1 and 5
Number of subjects: 387
Study 27243035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous Exercise (VE)
Number of subjects: 20
Study 25407279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan 30 mg
Number of subjects: 25
Study 25407279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan 90 mg
Number of subjects: 25
Study 25407279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan 120 mg
Number of subjects: 25
Study 25407279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan 240 mg
Number of subjects: 25
Study 25407279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 23302735 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg mifepristone once a day for 2 days + 200 µg misoprostol 48 hours later (G1 group)
Number of subjects: 200
Study 23302735 — intervention group
Group type: COMPARATOR
Intervention: 150 mg mifepristone + 600 µg misoprostol 48 hours later (G2 group)
Number of subjects: 200
Study 20575918 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobutton (n=13)
Number of subjects: 29
Study 20575918 — intervention group
Group type: COMPARATOR
Intervention: TransFix (n=16)
Number of subjects: 29
Study 18035097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 384
Study 18035097 — intervention group
Group type: COMPARATOR
Intervention: Vascular brachytherapy
Number of subjects: 384
Study 16095463 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ml 3% dextran 60 solution
Number of subjects: 110
Study 16095463 — intervention group
Group type: COMPARATOR
Intervention: 1000 ml acetated Ringer's solution
Number of subjects: 110
Study 12034106 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol measles and rubella (MR) vaccine
Number of subjects: 562
Study 12034106 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous measles and rubella (MR) vaccine
Number of subjects: 562
Study 10422534 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected conditions (wearing Kevlar army helmet and earplugs)
Number of subjects: 0
Study 10422534 — intervention group
Group type: COMPARATOR
Intervention: Bare‐head control condition
Number of subjects: 0
Study 7555467 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (7.5 mg/day)
Number of subjects: 51
Study 7555467 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg/day)
Number of subjects: 51
Study 7555467 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg/day)
Number of subjects: 51
Study 7555467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7555467 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID-induced mucosal damage
Number of subjects: 51
Study 2217669 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics before the procedure
Number of subjects: 515
Study 2217669 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 515
Study 83072 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 6
Study 83072 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 6
Study 83072 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (after crossover from placebo)
Number of subjects: 6
Study 31204849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0
Study 31204849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28707431 — intervention group
Group type: EXPERIMENTAL
Intervention: T. foenum‐graecum de‐husked seed extract, 600 mg per day for 12 weeks
Number of subjects: 115
Study 28707431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 25536539 — intervention group
Group type: EXPERIMENTAL
Intervention: Talk Test (TT) - Last Positive (LP) stage
Number of subjects: 16
Study 25536539 — intervention group
Group type: EXPERIMENTAL
Intervention: Talk Test (TT) - Equivocal (EQ) stage
Number of subjects: 16
Study 25536539 — intervention group
Group type: EXPERIMENTAL
Intervention: Talk Test (TT) - Negative (NEG) stage
Number of subjects: 16
Study 23392686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingosine-1-phosphate (S1P)
Number of subjects: 0
Study 23392686 — intervention group
Group type: COMPARATOR
Intervention: S1P(3)(-/-) mice
Number of subjects: 0
Study 23392686 — intervention group
Group type: COMPARATOR
Intervention: S1P(1)(fl/fl) mice and SNS-S1P(1)(-/-) mice
Number of subjects: 0
Study 21271379 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery 3 days after SEMS placement
Number of subjects: 49
Study 21271379 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery 10 days after SEMS placement
Number of subjects: 49
Study 21271379 — intervention group
Group type: COMPARATOR
Intervention: Emergent open surgery
Number of subjects: 49
Study 20079135 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg/kg bolus followed by continuous infusion of 0.1 microg x kg(‐1) x min(‐1)
Number of subjects: 90
Study 20079135 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg bolus followed by continuous infusion of 0.1 microg x kg(‐1) x min(‐1)
Number of subjects: 90
Study 20079135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 microg/kg bolus followed by continuous infusion of 0.01 microg x kg(‐1) x min(‐1)
Number of subjects: 90
Study 17904457 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil‐SR
Number of subjects: 22576
Study 17904457 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 22576
Study 17904457 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I obesity (BMI 30 to 35 kg/m2)
Number of subjects: 22576
Study 17904457 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II to III obesity (BMI 35 kg/m2 or more)
Number of subjects: 22576
Study 17904457 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (BMI 20 to<25 kg/m2)
Number of subjects: 22576
Study 15238028 — intervention group
Group type: EXPERIMENTAL
Intervention: Generation (participants generated some study words, e.g., hot‐c__)
Number of subjects: 0
Study 15238028 — intervention group
Group type: COMPARATOR
Intervention: Reading (participants read other study words, e.g., hot‐cold)
Number of subjects: 0
Study 15238028 — intervention group
Group type: EXPERIMENTAL
Intervention: Generation
Number of subjects: 0
Study 12877377 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (amoxicillin 750 mg x 2, doxycycline 100 mg x 2 or penicillin V 1500 mg x 2)
Number of subjects: 150
Study 12877377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 10584397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrox gas mixture
Number of subjects: 0
Study 10584397 — intervention group
Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 0
Study 10584397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 0
Study 10584397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrox
Number of subjects: 0
Study 10584397 — intervention group
Group type: COMPARATOR
Intervention: Air, Oxygen, Nitrox
Number of subjects: 0
Study 7784724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (1 mg/kg) administered via regular endotracheal tube (group 1)
Number of subjects: 60
Study 7784724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (1 mg/kg) administered via suction-catheter deep endobronchially (group 2)
Number of subjects: 60
Study 7784724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (1 mg/kg) administered via EDGAR-tube (group 3)
Number of subjects: 60
Study 7784724 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 4) with regular endotracheal tube without lidocaine administration
Number of subjects: 60
Study 2113848 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms norethisterone (NET)
Number of subjects: 20
Study 2113848 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms levonorgestrel (L‐NOG)
Number of subjects: 20
Study 486293 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 6
Study 486293 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg metoclopramide
Number of subjects: 6
Study 486293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 486293 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (general)
Number of subjects: 6
Study 31065703 — intervention group
Group type: EXPERIMENTAL
Intervention: GPM (GalliPro Max/B. subtilis, 500 g/ton)
Number of subjects: 384
Study 31065703 — intervention group
Group type: EXPERIMENTAL
Intervention: GPT (GalliPro Tect/B. licheniformis, 500 g/ton)
Number of subjects: 384
Study 31065703 — intervention group
Group type: COMPARATOR
Intervention: CON (basal diet)
Number of subjects: 384
Study 28084890 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group, median 1.8 h/week during adjuvant therapy (IQR 1.4-2.5)
Number of subjects: 227
Study 28084890 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 227
Study 28084890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 227
Study 28084890 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 227
Study 26410869 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (GECS)
Number of subjects: 64
Study 26410869 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse graduated compression stockings (PECS)
Number of subjects: 64
Study 26410869 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GECS and PECS
Number of subjects: 64